Efficacy and safety of etanercept in chronic immune-mediated disease

Volume: 13, Issue: 5, Pages: 649 - 661
Published: Mar 22, 2014
Abstract
Introduction: TNF-α inhibitors have demonstrated efficacy in large, randomized controlled clinical trials either as monotherapy or in combination with other anti-inflammatory or disease-modifying antirheumatic drugs in the treatment of chronic inflammatory immune-mediated diseases. Etanercept is a fusion protein that acts as a ‘decoy receptor’ for TNF-α. Areas covered: This paper evaluates the efficacy and safety of etanercept in patients with...
Paper Details
Title
Efficacy and safety of etanercept in chronic immune-mediated disease
Published Date
Mar 22, 2014
Volume
13
Issue
5
Pages
649 - 661
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.